VSV GPM
Alternative Names: Vesicular stomatitis oncolytic virus - China Grand Pharmaceutical and Helathcare/Shanghai Revolmmune Therapeutics Bio-technology; VSV-GPM - China Grand Pharmaceutical/RevolmmuneLatest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Shanghai Revolmmune Therapeutics Bio-technology
- Developer China Grand Pharmaceutical and Healthcare; Shanghai Revolmmune Therapeutics Bio-technology
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Colorectal-cancer in China (Parenteral)
- 30 Sep 2020 Preclinical trials in Colorectal cancer in China (Parenteral)
- 15 Jul 2020 China Grand Pharmaceutical and Healthcare in-licenses Vesicular stomatitis oncolytic virus technology from Shanghai Revolmmune Therapeutics Bio-technology